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were significantly associated with the time course of EEG vig-
ilance in the MDD group only. In both groups, IL-13 was sig-
nificantly associated with the course of EEG vigilance. In MDD 
compared to controls, a hyperstable EEG vigilance regulation 
was found, significant for group and group × time course in-
teraction. After controlling for wakefulness-promoting cyto-
kines, differences in vigilance regulation between groups re-
mained significant.  Conclusions: The present study dem-
onstrated a relationship between wakefulness-promoting 
cytokines and objectively measured EEG vigilance as an indi-
cator for brain  arousal. Altered brain arousal regulation in 
MDD gives support for future evaluation of vigilance mea-
sures as a biomarker in MDD. Since interactions between cy-
tokines and EEG vigilance only moderately differed between 
the groups and cytokine levels could not explain the group 
differences in EEG vigilance regulation, cytokines and brain 
arousal regulation are likely to be associated with MDD in in-
dependent ways.  © 2016 S. Karger AG, Basel 
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 Abstract 
 Background: In major depressive disorder (MDD), findings in-
clude hyperstable regulation of brain arousal measured by 
electroencephalography (EEG) vigilance analysis and altera-
tions in serum levels of cytokines. It is also known that cyto-
kines affect sleep-wake regulation. This study investigated 
the relationship between cytokines and EEG vigilance in par-
ticipants with MDD and nondepressed controls, and the influ-
ence of cytokines on differences in vigilance between the two 
groups.  Methods: In 60 patients with MDD and 129 controls, 
15-min resting-state EEG recordings were performed and vig-
ilance was automatically assessed with the VIGALL 2.0 (Vigi-
lance Algorithm Leipzig). Serum levels of the wakefulness-
promoting cytokines interleukin (IL)-4, IL-10, IL-13 and som-
nogenic cytokines tumor necrosis factor-α, interferon-γ and 
IL-2 were measured prior to the EEG.  Results: Summed wake-
fulness-promoting cytokines, but not somnogenic cytokines, 
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 The majority of patients suffering from major depres-
sive disorder (MDD) not only exhibit core symptoms of 
MDD such as depressed mood, reduced drive and loss of 
interest, but also disturbances pointing to a preponder-
ance of wakefulness-promoting over sleep-promoting 
(somnogenic) brain mechanisms. Among these symp-
toms are prolonged sleep onset latencies, impaired sleep 
maintenance, inner tension and difficulty relaxing. With-
in the arousal model of affective disorders these symp-
toms are associated with a high and hyperstable regula-
tion of vigilance, which is postulated to play an important 
pathogenetic role  [1] . Within this model, symptoms of 
sensation avoidance and social withdrawal are interpret-
ed as an autoregulatory reaction of the organism to this 
state of high brain arousal: the organism aims to avoid 
any further arousal-increasing sensory or social stimula-
tion. Using resting-state EEG (electro encephalography) 
recordings, a replicated finding is that patients with MDD 
compared to healthy controls show hyperstable EEG vig-
ilance regulation characterized by fewer and later transi-
tions to EEG signs of drowsiness or sleep onset  [2, 3] . 
 Cytokines, transmitters of the immune system, have 
been shown to be involved in both wakefulness regulation 
and the pathogenesis of depression. They influence sev-
eral neurotransmitter systems such as the serotonin, glu-
tamate and dopamine systems, and neuroendocrine sys-
tems such as the hypothalamic-pituitary-adrenal (HPA) 
axis, which are involved in sleep-wake-regulation and im-
plicated in the pathogenesis of depression  [4–6] . During 
states with increased proinflammatory cytokine produc-
tion or after proinflammatory cytokine administration, 
humans and laboratory animals exhibit anhedonia, psy-
chomotor slowing, sleepiness, fever and increased sensi-
tivity to pain, termed ‘sickness behavior’  [4, 7] . In depres-
sion, proinflammatory cytokines were found to interact 
with the HPA axis, to stimulate the serotonin-depleting 
indolamine-2,3-dioxygenase and to trigger serotonin 
reuptake  [6, 8, 9] . Levels of proinflammatory cytokines 
were repeatedly found to be elevated in depressed pa-
tients as well as in animal models of depression  [6, 10, 11] , 
potentially representing an inflammation-associated spe-
cific subtype of MDD  [12–14] and a target for new anti-
depressant treatment strategies  [15, 16] .
 Moreover, a body of studies applying objective and 
subjective measures for conditions of sleep and wakeful-
ness, performed in both preclinical and clinical settings, 
showed that proinflammatory cytokines like tumor ne-
crosis factor (TNF)-α and interferon (IFN)-γ exhibit 
sleep-inducing properties. Somnogenic properties of 
proinflammatory cytokines, best researched for TNF-α 
and interleukin (IL)-1β, presumably arise from activation 
of the humoral agents nuclear factor-kappa B (NF-κB) 
and nitric oxide. Somnogenic effects may be further pro-
moted by an impact on the HPA axis, including an in-
crease in growth hormone-releasing hormone  [5, 17–19] . 
States of low-grade inflammation with upregulation of 
cytokine signaling feature in disorders in which excessive 
daytime sleepiness is commonly observed, such as meta-
bolic syndrome  [20] , obstructive sleep apnea and HLA-
DR2-positive narcolepsy  [21, 22] . Cytokine levels are fur-
ther related to certain habits like daily napping and the 
extent of physical activity  [10] . Whereas the connection 
between sleep and cytokines has been more broadly in-
vestigated, little is known concerning the role of cytokines 
in arousal and wakefulness regulation. Predominately, 
anti-inflammatory cytokines such as IL-4, IL-10 and IL-
13 are regarded to have wakefulness-promoting effects. 
However, this was mostly concluded by the impact on 
sleep duration and sleep stage fractions in animal models 
 [17, 18, 23] . In these, the administration of IL-10 and IL-
13 reduced time spent asleep, probably by limiting the 
production of sleep-inducing TNF-α and IL-1 as well as 
interfering with transcription factor NF-κB  [24–28] . 
Wake-promoting cytokines further peak in concentra-
tions during daytime  [29] , levels of IL-10 reduce during 
sleep  [30] , sleep restriction leads to an increase in the IL-4 
to IL-2 ratio  [31] and insomniac men show higher levels 
of IL-4 than noninsomniac men  [32] .
 In the present study, we used a recently developed and 
validated EEG-based algorithm which allows objective 
assessment of different EEG vigilance stages from active 
wakefulness to sleep onset. The aim of this study was to 
explore the relationship between EEG vigilance regula-
tion and serum levels of wakefulness-promoting and 




 The 189 participants comprised 35 consecutively admitted de-
pressed patients from the Department of Psychiatry and Psycho-
therapy of the University Hospital Leipzig, 25 depressed patients 
from the outpatient clinic of the Integrated Research and Treat-
ment Center for Adiposity Diseases Leipzig (IFB) and 54 nonde-
pressed patients from the IFB and 75 community volunteers re-
cruited via announcements (intranet, internet, local newspapers). 
A mix of obese and nonobese subjects was made possible given a 




















   
   
   
   
   
   
   
   
   
   
   



























(data not shown). Evaluation of the inclusion and exclusion crite-
ria was performed in two stages. 
 Initial telephone screening comprised sociodemographic data, 
screening for somatic disorders and a checklist version of the 
Structured Clinical Interview for DSM-IV (SCID-I)  [33] . Then, for 
both community subjects and patients treated at the clinics, a full 
SCID-I was performed in cases of positive SCID screening or 
known diagnosis of depression. Further, current and past history 
of mental and physical health problems and laboratory investiga-
tions for current inflammation were assessed. 
 Exclusion criteria were other DSM-IV axis 1 disorders, any 
psychoactive medication in the past 7 days, use of illegal drugs, al-
cohol abuse within the past 6 months, a history of head injury with 
loss of consciousness exceeding 1 h, acute or chronic infection and 
major somatic disorders. Participants with known sleep apnea or 
obesity hypoventilation syndrome were also excluded. 
 A Hamilton Depression Rating Scale (HAMD-17)  [34] was 
performed in depressed participants. All participants completed a 
Beck Depression Inventory (BDI-II)  [35] and a sleep questionnaire 
(‘Schlaffragebogen A’; SF-A)  [36] assessing subjective sleep quality 
during the night preceding the EEG recording. The SF-A assesses 
five domains: ‘sleep quality’, ‘feeling of being refreshed in the 
morning’, ‘psychosomatic complaints during the sleep phase’, 
‘mental balance in the evening’ and ‘mental tiredness in the eve-
ning’. Written informed consent was obtained from all partici-
pants. The study was approved by Leipzig University Ethics Com-
mittee (No. 015-10-18012009).
 EEG Recordings 
 Fifteen minutes of resting-state EEG were recorded. All record-
ings were taken between 08: 00 and 18.00 h. Participants were in-
structed to keep their eyes closed, relax and not resist any urge to 
fall asleep. The EEG was recorded with a 40-channel QuickAmp 
amplifier (Brain Products GmbH, Gilching, Germany) from 31 
electrode sites according to an extended version of the interna-
tional 10–20 system at a sampling rate of 1 kHz, referenced against 
the common average using a low-pass filter at 280 Hz. Impedanc-
es were kept below 10 kΩ. EEG data were processed using a Brain 
Vision Analyzer 2.0 (Brain Products GmbH). EOG (electrooculo-
gram) electrodes were placed above the upper left eye and under 
the lower right eye. EEG raw data were filtered at 70 Hz (low-pass), 
0.5 Hz (high-pass) and 50 Hz (notch filter, range ± 2 Hz). EOG 
channels were screened for periods of open eyes which were ex-
cluded from further analysis. Eye movement artifacts were re-
moved with an independent component analysis approach by ex-
tracting 1–3 independent components that clearly represented 
vertical and horizontal eye movements. Likewise, persistent mus-
cle artifacts were removed using the independent component anal-
ysis method. Following this, segments with remaining muscle, 
movement, eye and sweating artifacts were marked for exclusion 
from further analysis.
 Assessment and Classification of EEG Vigilance 
 Each of the consecutive 900 one-second segments for each par-
ticipant was classified according to the seven EEG vigilance stages 
of the computer-based VIGALL (Vigilance Algorithm Leipzig; 
http://www.uni-leipzig.de/ ∼ vigall/):
 • Stage W with low-amplitude, non-alpha activity during an ac-
tivated state 
 • Stage A with dominant alpha activity corresponding to relaxed 
wakefulness (divided into substages A1, A2 and A3 according 
to the degree of spreading of alpha activity from occipital to 
more anterior cortices) 
 • Stage B with low-amplitude non-alpha (substage B1) and in-
creasing theta and delta activity corresponding to drowsiness 
(substage B2/3) 
 • Stage C with sleep spindles or K-complexes characterizing 
sleep onset 
 Percentages of EEG vigilance stages were computed by dividing 
the number of segments of a given stage by the number of non-
artifact segments [for a detailed description, see  3 ]. Further-
more, according to the respective vigilance stage, each segment 
was allocated to a measure ranging from the value 7 (highest vigi-
lance stage W) to 1 (sleep onset stage C). The 15-min resting EEG 
was then separated into fifteen epochs with a duration of 1 min 
(min 1, min 2, …, min 15) and five epochs with a duration of 3 min 
(min 1–3, min 4–6, …, min 13–15). Average vigilance values were 
computed for the respective epochs (online supplementary table; 
see www.karger.com/doi/10.1159/000441419).
 Cytokine Measurement 
 All blood draws were performed immediately preceding the 
resting-state EEG recordings. Blood samples were immediately 
centrifuged at 3,000 rpm for 10 min. The supernatant was aliquot-
ed and stored in nonabsorbing polypropylene 300-μl tubes. Probes 
of serum were shock-frozen in liquid nitrogen and stored in freez-
ers at –80  °  C until further measurement. Cytokines were measured 
using the Bio-Plex Pro TM human cytokine Th1/Th2 immunoassay 
from Bio-Rad, Germany, a 96-well kit that includes coupled mag-
netic beads and detection antibodies. This multiplex assay detects 
IL-2, IL-4, IL-5, IL-10, IL-12, IL-13, GM-CSF, IFN-γ and TNF-α. 
Levels of these cytokines and an evaluation of differences between 
depressed and nondepressed subjects in the present study sample 
have been reported  [10] . In the present article, we aimed to explore 
a possible relationship between cytokines and vigilance regulation 
and therefore only included those subjects with EEG recordings 
matching the inclusion criteria.
 Statistics 
 For differences in sociodemographic data and depression 
scores, Student’s t test (age, BMI), χ 2 test (sex) and Mann-Whitney 
U test (BDI-II) were performed. Of the 9 cytokines assayed, those 
with somnogenic properties (TNF-α, IFN-γ, IL-2) and wakeful-
ness-promoting properties (IL-4, IL-10, IL-13) were selected based 
on the literature  [17] . Z-transformations were performed for each 
of these 6 individual cytokine levels and Z-values for TNF-α, IFN-γ 
and IL-2 were summed to produce the covariate ‘somnogenic cy-
tokines’ and Z-values for IL-4, IL-10 and IL-13 to produce the co-
variate ‘wakefulness-promoting cytokines’.
 EEG vigilance stages were compared using the Mann-Whit-
ney U test due to a nonnormal distribution of stages, based on the 
Kolmogorov-Smirnov test. The average vigilance values for the 
fifteen 1-min and five 3-min epochs showed a normal distribu-
tion. The relationship between depression and the time course of 
EEG vigilance was examined in a 2 (‘group’: depressed vs. non-
depressed) × 5 (‘time’: min 1–3, min 4–6, min 7–9, min 10–12, 
min 13–15 epochs) repeated measures ANOVA, with the average 
vigilance value per 3-min epoch as the dependent variable and 




















   
   
   
   
   
   
   
   
   
   
   



























3-min blocks were performed with Scheffé tests with time of re-
cording as the covariate.
 Analyses of covariance with repeated measures (MANCOVA) 
were used to investigate the relationships between depression, cyto-
kine levels and the time course of EEG vigilance. In a first step, sep-
arate MANCOVAs were performed in the total sample and the two 
subgroups (depressed vs. nondepressed participants;  fig. 1 ), with the 
average vigilance value serving as the dependent variable and ‘time’ 
serving as the within-subject factor, controlled for levels of each sep-
arate cytokine or levels of somnogenic or wakefulness-promoting 
cytokines (covariate). Two separate 2 (between-subject factor 
‘group’) × 5 (repeated measure ‘time’) MANCOVAs were then per-
formed in the total sample, with levels of somnogenic or wakeful-
ness-promoting cytokines as the respective covariate and time of 
recording as the covariate. For  figure 2 , the subjects were allocated 
into groups of ‘high IL-13’ and ‘low IL-13’ when levels were below 
the 1st quartile (IL-13  ≤ 2.48 pg/ml, n = 49) or above the 4th quartile 
(IL-13  ≥ 8.44 pg/ml, n = 47). The IBM Statistical Package for the So-
cial Sciences (SPSS) program version 20.0 for Windows was used for 
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Nondepressed
 Fig. 2. Time course of EEG vigilance between groups of depressed 
and nondepressed participants. 
 Fig. 1. Time course of EEG vigilance between groups of partici-
pants with ‘high IL-13’ (4th quartile = IL-13  ≥ 8.44 pg/ml, n = 47) 
and ‘low IL-13’ (1st quartile = IL-13  ≤ 2.48 pg/ml, n = 49). 
 Table 1.  Differences in sociodemographics, depression scores, time of EEG recordings and sleep quality between groups of depressed 
and nondepressed participants
Depressed 
participants (n = 60)
Nondepressed 
participants (n = 129)
Test statistics p values
Age, years 39.30 ± 13.02 37.12 ± 12.85 T = –1.074 0.285
Sex (male/female) 30/30 30/81 χ2 = 2.764 0.096
BMI 29.61 ± 9.70 36.24 ± 12.11 T = 1.011 0.314
BDI-II score 27.19 ± 11.68 6.18 ± 6.69 Z = –9.702 <0.001
HAMD-17 score 17.56 ± 6.65 – n.a. n.a.
Recording time of day1, h 11:13 ± 2:13 12:03 ± 2:42 Z = –1.840 0.066
Sleep quality (SF-A) 2.67 ± 0.80 3.81 ± 0.67 Z = –7.938 <0.001
Refreshed in the morning (SF-A) 2.69 ± 0.90 3.33 ± 0.65 Z = –4.421 <0.001
Mental balance in the evening (SF-A) 2.27 ± 0.82 3.46 ± 0.71 Z = –7.506 <0.001
Mental tiredness in the evening (SF-A) 3.48 ± 0.96 2.94 ± 0.83 Z = –3.742 <0.001
Psychosomatic complaints during sleep (SF-A) 1.73 ± 0.70 1.33 ± 0.37 Z = –3.532 <0.001
Self-reported sleep duration, h/min 7/47 ± 1/73 7/18 ± 1/17 Z = –1.278 0.201
Data are presented as means ± SD unless otherwise indicated. Significant comparisons are in italics. n.a. = Not applicable.




















   
   
   
   
   
   
   
   
   
   
   




























 The depressed and nondepressed groups did not dif-
fer in age, sex or BMI. As expected, the depressed par-
ticipants showed significantly higher self-rated scores 
on the BDI-II, with overall moderate severity of depres-
sive symptoms according to HAMD-17 ( table  1 ). On 
the SF-A, the depressed participants reported reduced 
‘sleep quality’, reduced ‘feeling of being refreshed in the 
morning’, increased ‘psychosomatic complaints during 
the sleep phase’, reduced ‘mental balance in the eve-
ning’ and increased ‘mental tiredness in the evening’. 
Reported sleep duration did not vary between groups. 
The EEG recording was performed slightly later in the 
day in the nondepressed group ( table 1 ).
 EEG Vigilance and Cytokines 
 Repeated measures ANOVA analyses of EEG vigi-
lance by time for each of the cytokines revealed signifi-
cance for the factor ‘IL-13' in the total sample, and an 
‘IL-13 × time’ interaction in the total sample and in 
both depressed patients and controls ( fig.  1 ). For 
grouped cytokines, a significant interaction for ‘wake-
fulness-promoting cytokines × time’ was found within 
the total sample. Within the depressed group, there was 
a significant interaction ‘wakefulness-promoting cyto-
kines × time’. Within the nondepressed controls no in-
teraction ‘wakefulness-promoting cytokines × time’ 
could be found. No significant interaction for ‘somno-
genic cytokines × time’ was found within the total sam-
ple or separate groups ( table 2 ).
 EEG Vigilance in Depression 
 Comparisons of EEG vigilance stages between groups 
revealed a significantly higher amount of total A stages 
and substage A2 and a lower amount of total B stages in 
the depressed compared to nondepressed groups ( ta-
ble  3 ). Repeated measures ANOVA of EEG vigilance 
course between groups revealed a highly significant ef-
fect of the factor ‘group’ on the dependent variable ‘av-
erage vigilance value’. The interaction ‘group × time’ 
was also significant ( table 3 ). Post hoc tests revealed sig-
nificant group differences for the min 7–9, min 10–12 
and min 13–15 epochs ( fig. 2 ).
 Impact of Cytokine Levels on EEG Vigilance in 
Depression 
 ANOVA analysis of the dependent variable ‘average 
vigilance value’ between groups showed significant inter-






























































































































































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   



























‘wakefulness-promoting cytokines × time’ (F 2, 444 = 3.105, 
p = 0.037). ‘EEG vigilance’ trended for the factor ‘group’ 
(F 1, 185 = 3.416, p = 0.066) but not for ‘wakefulness-pro-
moting cytokines’ (F 1, 185 = 0.968, p = 0.326).
 Discussion 
 This is, to the authors’ knowledge, the first study com-
paring resting-state EEG measures and cytokine serum 
concentrations in unmedicated depressed and nonde-
pressed participants. The results demonstrate a positive 
association between EEG-based measures of brain arous-
al (EEG vigilance) and concentrations of cytokines in the 
total sample and separate groups, which was not related 
to differences in brain arousal regulation between MDD 
and nondepressed controls. 
 This positive association was not a general finding for 
all 6 cytokines investigated but limited to IL-13 and, pos-
sibly driven by IL-13, the grouped IL-4, IL-10 and IL-13 
cytokines with wakefulness-regulating properties. For 
the individual and summed somnogenic cytokines 
TNF-α, IFN-γ and IL-2, all mediators of proinflamma-
tory immune responses, no such association could be 
shown. Notwithstanding that proinflammatory cyto-
kines such as TNF-α have been most often implicated in 
the pathophysiology of depression  [12, 37] , our results 
indicate that anti-inflammatory, wakefulness-promot-
ing cytokines such as IL-4, IL-10 and IL-13 should be 
borne in mind when investigating specific features of de-
pression such as abnormalities in sleep-wake regulation. 
Both the anti-inflammatory and wakefulness-promoting 
properties of IL-13, levels of which are reported to be el-
evated in MDD  [10] , potentially arise from the suppres-
sion of important molecular pathway agents like second 
messenger nitric oxide release  [38] and, together with 
IL-4 and IL-10, by the blockade of the transcriptional fac-
tor NF-κB  [5] . Indirect sleep-inhibiting effects of these 
cytokines may also arise from the inhibition of the dif-
ferentiation and shift of naïve T cells into T-helper 1 cells 
and activation of macrophages, respectively, from a re-
duction of TNF-α and IFN-γ levels. Peripheral and hy-
pothalamic TNF-α has been suggested to show a direct 
impact on non-REM sleep and modulate molecular net-
works relevant for sleep regulation  [5, 17, 19] . TNF-α 
levels were linked with daytime sleepiness  [39] and levels 
increased after supplementation with sleep-inducing an-
tidepressants and antipsychotics  [40, 41] . Whilst IFN-γ-
 Table 3.  Occurrence of EEG vigilance stages between depressed and nondepressed groups and differences of EEG 





Test statistics p values Partial η2
Stage, %
Stage W 12.98 ± 16.57 12.50 ± 15.79 F=0.036 0.849 0.000
Stage A 52.62 ± 30.08 42.83 ± 28.65 F=4.636 0.033 0.024
Substage A1 22.61 ± 23.07 21.38 ± 21.61 F=0.126 0.723 0.001
Substage A2 27.26 ± 24.95 17.99 ± 19.79 F=7.572 0.007 0.039
Substage A3 2.76 ± 3.63 3.45 ± 5.76 F=0.763 0.383 0.004
Stage B 34.08 ± 26.72 43.51 ± 25.15 F=5.533 0.020 0.029
Substage B1 21.32 ± 20.98 27.06 ± 21.10 F=3.039 0.083 0.016
Substage B2/3 12.76 ± 17.59 16.45 ± 18.07 F=1.739 0.189 0.009
Stage C 0.32 ± 1.30 1.16 ± 4.33 F=2.164 0.143 0.011
Repeated measures ANOVA
Time F = 1.423 0.240 0.008
Group F = 3.929 0.049 0.021
Time × group F = 3.424 0.026 0.018
Post hoc min 1 – 3 4.96 ± 0.94 4.93 ± 0.87 F = 0.044 0.834 0.000
Post hoc min 4 – 6 4.75 ± 0.92 4.55 ± 1.06 F = 1.632 0.203 0.009
Post hoc min 7 – 9 4.64 ± 0.93 4.25 ± 1.12 F = 5.036 0.026 0.026
Post hoc min 10 – 12 4.48 ± 1.06 4.04 ± 1.03 F = 6.536 0.011 0.034
Post hoc min 13 – 15 4.36 ± 1.03 3.98 ± 1.12 F = 4.579 0.034 0.024




















   
   
   
   
   
   
   
   
   
   
   



























mediated sleep-inducing properties are considered to 
depend on the interaction with TNF-α, as deduced from 
symptoms of sleepiness and fatigue during infections 
and IFN treatments  [5, 17] , data is lacking on its role on 
wakefulness. Several lines of evidence link the immune 
response to arousal regulation, possibly via the HPA axis 
or monoaminergic transmitter systems  [1, 4, 5] . Subjects 
suffering from inflammation frequently exhibit tiredness 
or sleepiness mediated by the increased production of 
proinflammatory cytokines in the setting of ‘sickness 
 behavior’, which resembles depressive symptoms  [4, 7] . 
Narcolepsy, a disorder with increased daytime sleepi-
ness, was found to be associated with specific markers of 
the HLA system and increased production of proinflam-
matory cytokines  [21, 42, 43] . Cytokines not only influ-
ence wakefulness regulation, but their concentrations 
also change depending on sleep characteristics or follow-
ing sleep deprivation  [44–46] .
 Our finding of more stable EEG vigilance regulation in 
MDD is in agreement with previous studies  [2, 3] and ex-
tends past findings using a refined version of the VIGALL 
algorithm in a larger sample of unmedicated depressed 
patients. The pattern across the 15-min EEG sampling 
frame of fewer declines into lower EEG vigilance stages, 
and a greater percentage of high EEG vigilance stages in 
the unmedicated depressed group, supports the theory of 
hyperstable arousal regulation in MDD  [1] . This poten-
tial pathophysiological feature of depression is consid-
ered to be a state-dependent trait, with depressive symp-
toms both as features of the hyperstable brain arousal 
 regulation (e.g. sleep disturbances, diurnal variation of 
mood) and as a result of an autoregulation response to 
this (e.g. social withdrawal, sensation avoidance). Find-
ings of hyperstable brain arousal regulation are not exclu-
sive to MDD, having been recently demonstrated in ob-
sessive-compulsive disorder  [47] . This pathophysiologi-
cal overlap between the disorders may contribute to high 
reciprocal comorbidity rates  [48] . Our results of dimin-
ished sleep quality in depressed patients is also in accor-
dance with the literature  [49] and these sleep disturbanc-
es may be a result of hyperstable wakefulness regulation 
not allowing patients to reach lower arousal levels that 
would be needed to attain sleep or deep sleep.
 Despite the interactions found between cytokines 
and EEG vigilance herein as well as both altered brain 
arousal regulation and cytokine levels in MDD, cyto-
kines did not significantly influence EEG vigilance dif-
ferences between the groups. Therefore, our findings do 
not provide support for a pathogenic link between hy-
perstable brain arousal regulation and proinflammato-
ry/somnogenic or anti-inflammatory/wakefulness-pro-
moting cytokines. 
 There are several limitations of this study. As well as 
analyzing the impact of each cytokine on EEG vigilance 
regulation separately, we grouped cytokines into wake-
fulness-promoting and somnogenic cytokines based on 
a review of the published literature  [17] . This is a some-
what imprecise classification, grouping cytokines from 
results of experimentally and statistically heterogeneous 
previous studies. Another limitation is that both blood 
samples and EEG measurements were taken at varying 
hours of the day, between 8: 00 and 18: 00 h. Therefore, 
an influence of circadian rhythmicity on the levels and 
effects of cytokines cannot be excluded  [50, 51] . The 
temporal resolution of EEG and cytokine measures and 
the extent to which they may be linked to changes in 
brain arousal are also disparate. Whereas the EEG has 
the methodological strength of instant and objective 
vigilance recording, changes in peripheral cytokines 
show latency due to synthesis and secretion and the 
passing of the blood-brain barrier  [4] . Although not in-
vestigated to date, measurable changes in cytokine con-
centrations related to short-term, nonrecurring changes 
in EEG vigilance can hardly be expected, whereas a long-
term recording with, for example, sustained high vigi-
lance regulation, prolonged vigilance patterns could be 
accompanied by sustained changes in cytokine concen-
trations. Therefore, the methods applied in the present 
study may account for not finding a link between som-
nogenic cytokines and arousal patterns. The 15-min 
EEG recording time during which the vast majority of 
participants did not manifest signs of sleep onset may 
have been too brief to elicit or discern neurophysiologi-
cal connections between somnogenic cytokines and pa-
rameters of sleep onset. However, as most previous 
studies used subjective questionnaires to assess sleepi-
ness or wakefulness while investigating the relationship 
between cytokines and wakefulness regulation  [17] and 
as this is the first study investigating serum cytokine lev-
els together with EEG measurements combined with 
VIGALL, we think that this negative result is important 
to report.
 In conclusion, this study provides further evidence 
for hyperstable brain arousal regulation in depressed pa-
tients and for a putative role of the immune system in 
wakefulness regulation. The hyperstable brain arousal 
regulation in MDD and elevated cytokine levels in this 
disorder appear to be the most likely independent path-
ways relevant to the pathogenesis of MDD, a subject re-




















   
   
   
   
   
   
   
   
   
   
   



























between serum levels of cytokines and objective, algo-
rithm-based, measurement of EEG vigilance indicates 
the potential utility of studies combining EEG vigilance 
and EEG sleep measures, along with repeated cytokine 
assaying during the recordings, to elucidate this interest-
ing but little-investigated field of psychoneuroimmu-
nology.
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